Market News & Trends
Palisade Bio Announces First Subject Dosed in Phase 1 Study for Moderate-to-Severe Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it dosed its first subject in its Phase 1 clinical study of PALI-2108, an orally administered PDE4 inhibitor prodrug that…
Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial for Microcystic Lymphatic Malformations Treatment
Palvella Therapeutics, Inc. recently announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and…
Bespak & Orbia Fluor & Energy Materials Unite to Accelerate Transition to Climate-Friendly Inhalers
Bespak and Orbia Advance Corporation, S.A.B. de C.V. Fluor & Energy Materials recently announced a collaboration intended to accelerate the transition to climate-friendly inhalers utilising…
Lisata Therapeutics & Valo Therapeutics Announce Preclinical Research Collaboration
Lisata Therapeutics, Inc. and Valo Therapeutics Oy recently announce a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with…
SGS Expands Cutting-Edge Spray Drug Delivery Testing Capabilities in Belgium Health Science Laboratory
SGS has announced an expansion in its spray drug delivery testing capabilities at their laboratory in Wavre, Belgium. Utilizing the latest Malvern Spraytec system, SGS…
Rice Bioengineers Shed Light on Dosing Challenges for Cancer Immunotherapy
A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a potent immune-boosting protein that holds promise for…
Sonnet BioTherapeutics Announces Patent Covering a Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Candidates
Sonnet BioTherapeutics Holdings, Inc. recently announced the USPTO has issued US Patent No. 12,134,635 titled Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same, covering two…
Transgene & ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Transgene and ProBioGen recently announce they have entered into a license agreement for ProBioGen’s AGE1.CR.pIX suspension cell line. This partnership aims to add value by…
Nxera Pharma & Antiverse Enter Collaboration to Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Nxera Pharma and Antiverse recently announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative…
PrognomiQ Announces $34-Million Financing to Advance Development of Early Detection Test for Lung Cancer With Multi-Omics Platform
PrognomiQ recently announced its Series D financing of $34 million led by Seer, Inc., with participation from a new, large, strategic investor in the Diagnostics…
Nouscom’s Off-the-Shelf Neoantigen Immunotherapy Continues to Elicit Potent & Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to "Intercept" Cancer
Nouscom recently announced further promising data from the fully enrolled Phase 1b/2 study evaluating NOUS-209 for its potential to "intercept" cancer in Lynch Syndrome (LS)…
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Corporation recently announced the successful completion of its first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).…
EMA Confirms Acceptance of Marketing Authorization Application for a Proposed Biosimilar to Simponi
Alvotech and Advanz Pharma recently announced the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech’s proposed biosimilar to Simponi (golimumab),…
Can-Fite Anti-Obesity Drug Received Patent Allowance in Australia
Can-Fite BioPharma Ltd. recently announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson, currently being developed for the…
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
Conduit Pharmaceuticals Inc. recently announced the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from…
SGS Announces Expansion of Biopharmaceutical Testing Capabilities
SGS recently announced it has added new capacity and capabilities at its center of excellence in Lincolnshire, IL. This expansion adds new instrumentation and expertise…
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease & Neuroscience Pipeline
AbbVie and Aliada Therapeutics recently announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier…
Quotient Sciences & Medicines for Malaria Venture Announce Dosing of First-Ever Long-Acting Injectable for Malaria Prevention to Study Volunteers
Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for a long-acting injectable (LAI) preventive compound for malaria. The trial, conducted in healthy…
Intensity Therapeutics & The Swiss Group for Clinical Cancer Research SAKK Announce First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK are collaborating in the INVINCIBLE-4 Study, a Phase 2 trial to treat patients…
SGS Launches New Consultancy Services to Transform & Accelerate Clinical Trial Submissions
SGS, the world’s leading testing, inspection and certification company, recently launched its pioneering CDISC Open Rules Consultancy, a new service designed to transform and accelerate…
